In 1996, Druker et al. [6] reported the in vitro effects of a specific inhibitor of the BCR-ABL tyrosine kinase on CML cell lines for the first time. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.